Anticancer Compounds Targeting Cancer Stem Cells via ABCG2 Selectivity
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current cancer treatments, particularly chemotherapy, are ineffective in targeting cancer stem cells (CSCs), which are responsible for uncontrolled cell proliferation and cancer recurrence.
Innovation Solution
Development of specific compounds, such as those represented by Formulas V to XI, which demonstrate preferential toxicity towards malignant cells, particularly in breast and prostate cancer cell lines, without affecting normal lymphocytes.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If standard chemotherapy is used to target dividing cancer cells, then most dividing cancer cells are killed, but quiescent or slow-dividing cancer stem cells are not targeted and cancer recurrence occurs
Solution Approach 1:
The patent applies local quality by designing compounds with specific molecular structures (Formulas I-IV with defined R1-R13 substituents) that exhibit preferential toxicity towards cancer stem cells while sparing normal cells. The compounds are engineered to interact specifically with biological targets unique to or overexpressed in CSCs, such as ABCG2 transporter inhibition, thereby achieving state-specific targeting rather than blanket cytotoxicity.
Solution Approach 2:
The patent employs parameter changes by systematically varying molecular parameters (substituent groups R1-R13, molecular weight, lipophilicity) to optimize compound properties for selective CSC targeting. The structure-activity relationship studies demonstrate how modifying chemical parameters enhances preferential toxicity towards CSCs while maintaining selectivity, transforming the general cytotoxic approach into a targeted therapy.
2Reliability
If compounds with high toxicity towards cancer cells are developed, then anticancer activity increases, but selectivity between cancer cells and normal cells may be compromised
Solution Approach 1:
The patent utilizes the ABCG2 transporter as an intermediary mechanism to achieve selective toxicity. Normal cells express functional ABCG2 that pumps out the compounds, protecting them from damage. Cancer stem cells either overexpress or have dysfunctional ABCG2, allowing the compounds to accumulate and exert toxic effects. This intermediary mechanism enables high anticancer activity while preserving normal cell viability.
Solution Approach 2:
The compounds exhibit differential biological effects based on the local quality of target cells. By designing molecules that specifically interact with CSC-marked cells (through ABCG2 inhibition or other CSC-enriched targets), the patent achieves localized toxicity only where needed, sparing normal lymphocytes and other healthy cells from harmful effects.
3Measurement precision
If molecularly-targeted therapies are used to specifically target cancer cells, then treatment precision improves, but treatment cost increases significantly
Solution Approach 1:
The patent develops small molecule compounds (Formulas I-IV) that can be synthesized through conventional organic chemistry methods, making them potentially more cost-effective than large molecule biologics. These small molecules serve as disposable therapeutic agents that can be produced at lower cost while maintaining targeted precision against CSCs, providing an economically viable alternative to expensive molecularly-targeted therapies.
Data Source
Figure 1~2
Figure 3~4
Figure 5~6
AI summary
The present invention discloses compounds for inhibition of uncontrolled cell proliferation particularly in cancer stem cells. Particularly, the invention relates to compounds of Formula III to XIV for the treatment of cancer, such as breast and prostate cancer.